- Company
- Imfinzi for liver cancer is expected to land in Korea soon
- by Eo, Yun-Ho May 30, 2023 05:33am
- According to related industries, the Ministry of Food and Drug Safety is in the process of final review for approval of Imjudo, a CTLA-4 inhibitor. Final approval is expected in the second half of the year. The first indication for Imfinzi and Imjudo combination therapy is liver cancer. The combination therapy is the only dual immunotherapy
- Company
- Reimb in progress for 1st endometrial cancer immunotherapy
- by Jung, Sae-Im May 30, 2023 05:33am
- Will the latecomer cancer immunotherapy ‘Jemperli (dostarlimab)’ from GSK be reimbursed as the first cancer immunotherapy in endometrial cancer? With cancer immunotherapies changing the treatment paradigm for the first time in decades, the demand in the field to speed up the reimbursement progress has also been increasing. in the field.
- Company
- Ebixa 20mg may be prescribed at general hospitals in Korea
- by Eo, Yun-Ho May 26, 2023 06:47am
- The high-dose formulation of the Alzheimer’s treatment ‘Ebixa’ has landed at general hospitals in Korea. According to industry sources, Lundbeck Korea’s ‘Ebixa (memantine) tablet 20mg’ passed the drug committees of medical institutions in Korea, including Seoul National University Hospital, Seoul Asan Medical Center, Sinchon Severan
- Company
- Lucentis sales fell 34%
- by Chon, Seung-Hyun May 26, 2023 06:47am
- Humira, Avastin, Herceptin, and Mabthera also saw drug prices cut after entering the market for similar drugs. Domestic sales of Lucentis, an eye disease treatment, fell by more than 30%. As Chong Kun Dang and Samsung Bioepis launched biosimilars, drug prices went down and sales took a direct hit. New drugs from multinational pharmaceutical comp
- Company
- Shingles vaccine Shingrix occupies 29% of market in 3 months
- by Jung, Sae-Im May 26, 2023 06:47am
- GSK’s shingles vaccine ‘Shingrix’ occupied 29% of the market in Q1 this year. In only 3 months of its release, it beat MSD’s ‘Zostavax’ and ranked 2nd in the market. The company has made a smooth start by actively conducting marketing activities in partnership with a domestic pharmaceutical company. According to the market research inst
- Policy
- "Nurturing biopharmaceuticals as the second semiconductor"
- by Kang, Shin-Kook May 25, 2023 11:05pm
- Deputy Prime Minister and Minister of Strategy and Finance Choo Kyung-ho announced that he would soon announce a plan to foster the bio-industry, saying he would foster the second semiconductor for biopharmaceuticals. On the 24th, Deputy Prime Minister Choo visited the Aprogen plant in Osong to inspect the biopharmaceutical production site and s
- Policy
- Welireg·Camzyos are approved in Korea
- by Lee, Hye-Kyung May 25, 2023 05:46am
- Welireg, a treatment for von Hippel-Lindau and VHL disease characterized by multiple tumors, and Camzyos, which is used to improve motor function and symptoms in patients with NYHA class II-III obstructive hypertrophic cardiomyopathy, received domestic product approval. It announced on the 24th that it had approved Welireg of MSD Korea and Ca
- Company
- BMS’s oHCM drug Camzyos approved in Korea
- by Jung, Sae-Im May 25, 2023 05:46am
- BMS Korea (Country Manager: Hye Young Lee) announced on the 24th that the Ministry of Food and Drug Safety has approved the company’s obstructive hypertrophic cardiomyopathy (oHCM) treatment ‘Camzyos (mavacamten)’ to treat adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM)
- Company
- Latecomer new CML drug Bosulif attempts reimb in Korea
- by Eo, Yun-Ho May 25, 2023 05:46am
- The latecomer leukemia treatment ‘Bosulif’ is attempting to receive reimbursement in Korea. According to industry sources, Pfizer Korea submitted an application for its Chronic Myelogenous Leukemia (CML) treatment Bosulif (bosutinib), and is receiving a review for its reimbursement. The drug, which was approved in January in Korea,
- Company
- Seven times stricter standards
- by Chon, Seung-Hyun May 25, 2023 05:46am
- Health authorities have prepared new standards for managing impurities in Januvia, a diabetes treatment. Prior to the release of Januvia generics, pharmaceutical companies were requested to only ship products within the newly set standard. Pharmaceutical companies are busy with quality control by presenting a standard that is seven times str
